Beinaglutide shows up in searches about GLP-1 peptides, but it has no FDA-approved label or marketing status in the United States. Here is what the available identity and trial data actually show.
Key takeaways
- Beinaglutide is investigational in the United States, with no FDA-approved label or brand name.
- It is a large synthetic peptide, molecular formula C149H225N39O46, molecular weight about 3298.6 daltons.
- Three trials are registered, all involving type 2 diabetes populations.
- One trial is recruiting, one is completed, and one has an unknown status.
- No adverse event report data is currently available for this compound.
What beinaglutide is
Beinaglutide is a synthetic peptide cataloged under PubChem CID 16209124. Its chemical identity is well defined, with a molecular formula of C149H225N39O46 and a molecular weight near 3298.6 daltons. No FDA-approved label exists for it, so there is no official U.S. indication, mechanism statement, or brand name to reference.
What the trial record shows
Three trials are registered for beinaglutide, and all three involve people with type 2 diabetes. One trial compares beinaglutide with dulaglutide for glucose control and weight loss in people who are overweight or have obesity, though its current status is unknown. A second trial is recruiting participants to compare continuous subcutaneous beinaglutide with an insulin pump approach in newly diagnosed type 2 diabetes patients. A third trial, now completed, compared beinaglutide with glargine therapy for glycemic variability in type 2 diabetes. These studies describe research activity only and do not establish that the compound is safe or effective for any use.